FDA And Industry Set Out GDUFA III Priorities
Focusing Initially On First-Cycle Approvals And Priority Assessment Improvements
Both first-cycle approvals and priority assessment improvements have been the subject of questions and criticism as the FDA and industry attempt to boost generic competition.
